Serina Therapeutics’ Parkinson’s trial update — a concise news article previewing cohort 1 dosing completion and an upcoming blinded safety review.
Key Takeaways
- Serina completed enrollment and dosing of all eight patients in Cohort 1 of its registrational trial
- Independent Safety Monitoring Committee will perform a blinded review of Cohort 1 safety and tolerability
- SER-252 is an investigational apomorphine therapy using a POZ poly(2-oxazoline) platform to enable controlled release